dimethylglycine has been researched along with Down Syndrome in 2 studies
dimethylglycine: metabolic product of calcium pangamate; mutagen when mixed with nitrite; RN given refers to parent cpd
N,N-dimethylglycine : An N-methylglycine that is glycine carrying two N-methyl substituents.
Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The gene for cystathionine beta-synthase (CBS) is located on chromosome 21 and is overexpressed in children with Down syndrome (DS), or trisomy 21." | 7.71 | Homocysteine metabolism in children with Down syndrome: in vitro modulation. ( Chango, A; James, SJ; Melnyk, S; Pogribna, M; Pogribny, I; Yi, P, 2001) |
| "The gene for cystathionine beta-synthase (CBS) is located on chromosome 21 and is overexpressed in children with Down syndrome (DS), or trisomy 21." | 3.71 | Homocysteine metabolism in children with Down syndrome: in vitro modulation. ( Chango, A; James, SJ; Melnyk, S; Pogribna, M; Pogribny, I; Yi, P, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Obeid, R | 1 |
| Hartmuth, K | 1 |
| Herrmann, W | 1 |
| Gortner, L | 1 |
| Rohrer, TR | 1 |
| Geisel, J | 1 |
| Reed, MC | 1 |
| Nijhout, HF | 1 |
| Pogribna, M | 1 |
| Melnyk, S | 1 |
| Pogribny, I | 1 |
| Chango, A | 1 |
| Yi, P | 1 |
| James, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind Placebo Controlled, Cross-over Trial of Subcutaneous B12 on Behavioral and Metabolic Measures in Children With Autism.[NCT00273650] | Phase 2/Phase 3 | 30 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for dimethylglycine and Down Syndrome
| Article | Year |
|---|---|
Blood biomarkers of methylation in Down syndrome and metabolic simulations using a mathematical model.
Topics: Adolescent; Adult; Betaine; Biomarkers; Case-Control Studies; Child; Child, Preschool; Choline; Cyst | 2012 |
Homocysteine metabolism in children with Down syndrome: in vitro modulation.
Topics: Adenosine; Case-Control Studies; Child; Chromatography, High Pressure Liquid; Cystathionine; Cystath | 2001 |